NousCom wraps up Series B round
NousCom, a Swiss oncology company, has closed its Series B funding round at 42 million euros. Abingworth was the lead investor. Also, 5AM Ventures, LSP and Versant Ventures participated in the round.
6 November 2017•4 mins read
